Saint Louis University Eye Institute St. Louis, MO, USA
Current standard management of choroidal neovascular membranes developing secondary to agerelated macular degeneration consists of thermal laser photocoagulation and photodynamic therapy based on the lesion location, size and fluorescein angiographic characteristics. In the next several years, numerous antiangiogenic substances (including Pegaptanib, Ranibizumab, and Anecortave Acetate) will be available and possibly superior to the current alternatives for use as monotherapy or combination therapy as the standard care for subfoveal CNVM. However, the benefit and cost of these agents and other alternative treatments should be well studied and assessed for the social, demographic and economical status of the patient population in the countries these are to be adopted. Keywords :
